Qiagen NV

NYSE:QGEN   10:33:57 AM EDT
47.66
+0.33 (+0.70%)
Products

Qiagen And Diasorin Widen Access To Latent TB Testing In U.S., Gain FDA Approval

Published: 11/29/2021 06:23 GMT
Qiagen NV (QGEN) - Qiagen and Diasorin Widen Access to Latent Tb Testing in the U.S. With FDA Approval of Quantiferon®-tb Gold Plus Assay on Liaison® Xs.
Additional U.S. Approval for Liaison® Xs Platform Builds on FDA Approval in 2019 for Quantiferon Assay Running on Diasorin's Liaison(®) Xl Analyzer.
Collaboration Now Provides Full Range of Automation Platforms for Tb Testing Options to Customers, Ranging From Small Healthcare Clinics to Larger Hospitals and Reference Laboratories.